> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Reports 4.1% Ironwood Stake As Drugmaker Raises Its Annual Revenue Outlook
- URL: https://www.bullished.co/state-street-reports-4-1-ironwood-stake-as-drugmaker-raises-its-annual-revenue-outlook-eed2d4aa/
- Published: 2026-11-10T13:47:46.000Z
- Updated: 2026-11-10T13:47:46.000Z
- Description: The holding dates to September 30, and State Street certified it was not seeking to influence the drugmaker's control.
- Author: Matteo Parrino
- Tags: SEC Filings, IRWD, Industry: Healthcare

State Street reported a [4.1% stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000678/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Ironwood Pharmaceuticals](https://www.bullished.co/tag/irwd/), which develops and sells medicines for gastrointestinal and rare diseases, in a passive ownership disclosure filed Tuesday. The position totaled 6,723,774 common shares as of September 30, rather than measuring a purchase on the filing date.

## A Passive Position With Voting Power

State Street had [shared voting power](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000678/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over 6,516,093 shares and shared authority to dispose of the full holding. It reported no sole voting or disposal power.

State Street certified that the securities were obtained and held as part of its ordinary business, not for the purpose or effect of changing or influencing Ironwood's control. The percentage applies to Ironwood's common-stock class on the disclosure's beneficial-ownership basis.

## Linzess Supports A Higher Forecast

Ironwood's earnings report paired a quarterly revenue miss against the Zacks consensus estimate with a [higher revenue forecast](https://finance.yahoo.com/markets/stocks/articles/irwd-q3-earnings-beat-revenues-170600165.html?ref=bullished.co) for 2026\. The company now expects $485 million-$510 million, compared with its earlier $460 million-$485 million range, and projects higher U.S. Linzess sales.

The Linzess collaboration with AbbVie contributed [$129.9 million](https://finance.yahoo.com/markets/stocks/articles/irwd-q3-earnings-beat-revenues-170600165.html?ref=bullished.co) to Ironwood's third-quarter revenue of $133 million. Ironwood and AbbVie divide U.S. linaclotide net profits and losses equally; Ironwood also receives royalties from overseas partners.

Linzess treats irritable bowel syndrome with constipation and other constipation conditions in adults and certain pediatric patients. Linaclotide also sells under the Constella name in overseas markets, including Canada, Mexico, Japan, China and certain European countries. The U.S. supplied 97.7% of Ironwood's revenue in 2025.

Shares rose 6.9% after the earnings report and outlook increase, taking their year-to-date gain to 19.6%, against a 0.8% industry decline. Ironwood's market value was $775 million as of 8:44 a.m. ET Tuesday.

Alongside its commercial linaclotide business, Ironwood is developing apraglutide for short bowel syndrome patients who rely on intravenous nutrition or fluid support.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: IRONWOOD PHARMACEUTICALS INC (IRWD)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000678/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock Up](https://finance.yahoo.com/markets/stocks/articles/irwd-q3-earnings-beat-revenues-170600165.html?ref=bullished.co) — Yahoo Finance

### More on Ironwood Pharmaceuticals

- [Ironwood Targets $485–$510 Million In Revenue As LINZESS Clears Last Year's Sales](https://www.bullished.co/ironwood-targets-485-510-million-in-revenue-as-linzess-clears-last-years-sales-9535b7d7/)

[All Ironwood Pharmaceuticals (IRWD) coverage →](https://www.bullished.co/tag/irwd/)